StreetSmart Live! Presents Omineca Mining and Metals Ltd on 10/08/2020. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update


Creator of Antibiotic-Free Livestock Supplement Extends Reach in Mexico
News Update

Share on Stocktwits


Avivagen reports that it has gained both new customers and increased access to prospective ones.

Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release that in Mexico, it garnered orders from two new customers for its OxC-beta™ Livestock product and joined two industry associations.

"We are very excited to expand the reach of OxC-beta™ Livestock in Mexico through these new client agreements and important alignments," Avivagen CEO Kym Anthony said in the release.

These new customers are Forrajes Tesistant, the owner of numerous swine farms and a commercial feed mill, and Prolea, the owner/manager of multiple dairy, poultry and swine farms and a commercial feed mill. Both companies placed an introductory order with Avivagen for 50 kilograms of OxC-beta Livestock.

The Ottawa-based life sciences firm joined "two of the most important and influential livestock feed and dairy production associations in Mexico," according to the release, as part of a new strategic plan Avivagen recently developed with assistance from Meyenberg International Group, a global expansion consulting firm.

ANFACA, the Asociación Nacional de Fabricantes de Alimentos Para Consumo Animal, is a Guadalajara-based organization for livestock producers and suppliers. It is composed of member companies like Forrajes Tesistant in the Jalisco area, which leads Mexico in agricultural production.

AMEPA, the Asociación Mexicana de Productores de Alimentos, is a feed millers group based in Mexico City. Its members include Prolea, Gramosa and large dairy operators in northern Mexico.

The company noted that these associations will afford Avivagen increased access to feed mills and farms throughout Mexico. For one, they will offer OxC-beta Livestock to their members but, also, will carry out trials for further use of the product in the region.

"We anticipate that our memberships with ANFACA and AMEPA will enable us to broaden and deepen our customer base and greatly extend the reach and usage of our proprietary and industry-leading alternative to antibiotics to a much wider market throughout the country," Anthony added.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe